Strong capabilities in PROTAC discovery by Viva Biotech
Unique methods and research strategies in PROTAC linker development
Repurpose a known BRD4 binder to new degraders using PROTAC acceleration kit and advanced linkerology
Rational optimization of PROTAC structure via structure-based biophysical methods
On June 21st, Viva Biotech hosted a Viva BioInsights webinar titled “Unveiling the PROTAC Revolution: Advancing Drug Discovery through Targeted Protein Degradation”. Dr. Michael Roy, Team Leader/Senior Research Officer, ACRF Chemical Biology Division (WEHI), along with Dr. David Taddei, Vice President of Medicinal Chemistry at Viva Biotech's subsidiary SYNthesis Med Chem, and Dr. Jean-Marc Garnier, Senior Director of Medicinal Chemistry at SYNthesis Med Chem, shared their extensive experience in the PROTAC field. They discussed the design and development processes of PROTACs, providing valuable insights from their years of research.
Dr. David Taddei: Viva Biotech offers a comprehensive PROTAC service from gene to CMC/CDMO. In the preclinical stage, Viva Biotech has a holistic R&D service system that includes protein production and structure research, drug screening, molecular design and synthesis, and final evaluation. Emphasizing unique methods and research strategies in PROTAC linker development, Viva's PROTAC technology platform collaborates with its proprietary DEL technology platform to deliver more customized and efficient services for clients' drug discovery needs.
Dr. Jean -Marc Garnier: BRD4 is implicated in the development of several cancers, making it a promising target for cancer therapy. BRD4 binders have the potential to treat various cancers, including breast cancer, prostate cancer, and leukemia. By starting with a known patented BRD4 binder, we can repurpose a known POI binder into new heterobifunctional degraders using Viva Biotech's PROTAC acceleration kit and advanced linkerology. This approach enhances degradation potency and improves in vitro metabolism.
Dr. Michael Roy: Through the study of the structures of SMARCA2 (BRM) and SMARCA4 (BRG) in BAF complexes and a case study of MZ1 in ternary complex dynamics, strategies for exploiting structure and biophysics in rational PROTAC optimization are presented.
As part of our Global Team of Program Managers, David is based in Montreal, Canada, and oversees a portfolio of North American and European Clients. He also works along Dr. Garnier on the development of VIVA's Chemistry-enabling Platforms like the PROTAC Libraries. David is a seasoned Drug Hunter from his career at Sygnature Discovery (UK), where he led or contributed to multidisciplinary research, including the discovery of Inobrodib, a first-in-class oral dual bromodomain inhibitor drug against multiple specific cancer types, and several Kinase Inhibitors as inhaled candidates for the treatment of COPD and Asthma.
Jean-Marc is an experienced program manager in drug discovery. He has led the medicinal chemistry of a first-in-class necroptosis inhibitor program and has been named as an inventor in over 10 granted patents. With a PhD in organic chemistry, he has worked in various roles at Pfizer-SRG, Peakdale Chemistry Services, and the Walter and Eliza Hall Institute of Medical Research. Jean-Marc joined SYNthesis in 2016 and is highly skilled in target validation, fragment-based drug discovery, and pre-clinical candidate selection.
Dr. Michael Roy, a leading medicinal chemist/structural biologist, is currently based at WEHI in Melbourne. His research centers around targeted protein degradation, utilizing small molecules, chemical biology, and structural approaches to investigate and target cancer signaling pathways. During his postdoctoral work at the University of Dundee under Professor Alessio Ciulli, Michael played a significant role in developing ACBI1 and ACBI2, which are degraders targeting SMARCA2/4 subunits of the BAF chromatin remodeling complex. Recently, as a Project Director in an international PROTAC collaboration between WEHI and Boehringer Ingelheim, Michael has co-led a team of talented researchers focused on developing oncology-related PROTACs.
For video replay，please provide the following details.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us